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Phytochemicals are generally defined as secondary metabolites in plants that 
play crucial roles in their adaptation to a variety of environmental stressors. 
There is a great body of compelling evidence showing that these metabolites 
have pronounced potentials for regulating and modulating human health and 
disease onset as shown by both experimental and epidemiological approaches. 
Concurrently, enormous efforts have been made to elucidate the mechanism of 
actions underlying their biological and physiological functions. For example, 
the pioneering work of Tachibana et al. uncovered the receptor for 
(-)-epigallocatechin-3-gallate (EGCg) as 67kDa laminin receptor, which was 
shown to partially mediate the functions of EGCg such as anti-inflammatory, 
anti-allergic, and anti-proliferative activities. Thereafter, several protein kinases 
were identified as binding proteins of flavonoids including myricetin, quercetin, 
and kaempferol. Isothiocyanates, sulfur-containing phytochemicals present in 
cruciferous plants, are well known to target Keap1 for activating the 
transcription factor Nrf2 for inducing self-defensive and anti-oxidative gene 
expression. In addition, we recently identified CD36 as a cell surface receptor 
for ursolic acid, a triterpenoid ubiquitously occurring in plants. Importantly, the 
above mentioned target proteins are indispensable for phytochemicals to 
exhibit, at least in part, their bioactivities. Nevertheless, it is reasonable to 
assume that some of the activities and potential toxicities of metabolites are 
exerted via their interactions with unidentified, off-target proteins. This notion 
may be supported by the fact that even the rationally designed drugs 
occasionally display off-target effects and induce unexpected outcomes, 
including toxicity. Here we update the current status and future directions of 







In 1993, Swinbanks and O'Brien described the status of development of 
physiologically functional food in Japan in a column entitled ‘Japan explores 
the boundary between food and medicine’ (1). Long before that publication, 
ancient society had knowledge of medicinal usage of domestic plants as local 
remedies for injury, epidemic diseases, and other maladies. Even now, 
traditional herbs and spices are used as surrogate and alternative medicines in 
many countries.  
In nature, plants biosynthesize chemical metabolites, which have 
diversity in terms of their chemical structures and biological functions. Those 
are divided into 2 groups of compounds, i.e., primary and secondary 
metabolites, based on their fundamental roles in plants. The former consist of 
compounds essential for vital activities, e.g., amino acids, carbohydrates, and 
lipids, while the latter are biosynthesized to adapt to environmental stressors 
such as ultraviolet (UV) light, invading microorganisms and insects, and 
drought. Some secondary metabolites are continuously produced in plants, 
whereas others are newly formed in accordance with stress signals. Flavonoids 
are interesting phytochemicals that have versatile biological functions including 
self-protection from UV light and anti-fungal effects. Similarly, some volatile 
terpenoids are recognized to serve as sex pheromones or chemical cues for 
emergency. ‘Phytoalexin’ is the term used to describe anti-microbial substances 
synthesized in plants that accumulate rapidly in areas of incompatible pathogen 
infections. In addition, ‘allelopathy’ is a biological phenomenon by which plants 
produce chemicals that influence the growth, survival, and reproduction of 
other plants. It is also worth noting that amazingly high proportions of the 
bioactive compounds in foods belong to the group of secondary metabolites, 
including phytoalexins (2). 
As will be discussed in more detail, these secondary metabolites have 
been shown to have diverse bioactivities in various evaluation systems, ranging 
from test tube experiments to human intervention studies, while the 
mechanisms of their actions have been addressed by numerous researchers. 
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However, in spite of accumulated mechanistic data, how phytochemicals 
exhibit physiological functions remains ambiguous and not fully elucidated. 
This can be easily agreed when comparing with synthetic drugs. Recent 
remarkable progress in molecular modeling and combinatorial chemistry has 
enabled chemists to rationally design drugs that display specific interactions 
with target molecules with high efficacy and fewer side-effects. It is not difficult 
to dissect their mechanisms of action, because most, if not all, of their targets are 
already known and these drugs were designed for target proteins at optimized 
affinity. The goal of this type of pharmacological approach is to confirm their in 
vivo efficacy in rodent experiments as well as clinical trials (Fig.1).  
In contrast, the major approach in the field of food functional science is 
to first investigate the efficacy of plant extracts or phytochemicals in cellular or 
animal models, followed by mechanistic studies (Fig.1), as some of the existing 
mechanistic information is inadequate to fully perceive their mode of actions. 
For example, if a phytochemical seems to prevent chemical carcinogenesis via 
suppression of oncogene induction, the question regarding how it suppressed 
the induction persists. That is, the roles of upstream signaling molecules 
involved in oncogene induction should further be explored. Furthermore, if an 
upstream signaling molecule is implicated to play a substantial role, direct 
inhibition and/or disruption of further upstream signaling molecules must be 
determined. Identification of the primary targets of phytochemicals is required 
to gain insight into how they exhibit physiological functions in biological 
systems. In 2004, Tachibana and coworkers published their excellent work on 
identification of the receptor for (-)-epigallocatechin-3-gallate (EGCg, Fig. 2) as a 
67kDa laminin receptor (67LR) (3). As noted following, this pioneering work 
stimulated many other researchers to search for other receptors and binding 
proteins of EGCg, as well as those of other phytochemicals (4,5), which opened 
a great window for food science of the next dimension. In this review article, we 
highlight the molecular targets of food phytochemicals including flavonoids, 
terpenoids, and sulfur-containing compounds, in discussion of the impact of 
precise understanding of mechanisms of action. 
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Brief overview of typical phytochemicals and their bioactivities 
Polyphenols 
 
Secondary metabolites can be categorized into several groups based on their 
chemical structures. For example, flavonoids, one of the largest categories, have 
a basic carbon skeleton of C6-C3-C6 bearing phenolic hydroxyl group(s). 
Flavonoids are further divided into several subgroups, such as flavones, 
flavanones, flavonols, catechins, anthocyanins, and others, which differ in 
regard to the extent of conjugation system, and presence or absence of carbonyl 
group and hydroxyl group at the 3-position. The most explicit bioactivity of 
flavonoids may be their antioxidant effects, which are largely dependent on the 
number of phenolic hydroxyl groups and their locations in a benzene ring. 
Their potent anti-oxidative activities are broadly attributable to their catechol 
(1,2-diphenols) and pyrogallol (1,2,3-triphenols) structures. These functional 
moieties have chemical characteristics to scavenge reactive oxygen species 
(ROS) through formation of an o-benzoquinone counterpart. However, it should 
be pointed out that they concurrently have pro-oxidative properties, which 
have some associations with potential toxicity (6), and are dependent on 
experimental conditions. Another noticeable biochemical activity is modulation 
of protein functions through interactions between their hydroxyl groups and 
amino and carbonyl groups in proteins. This allows flavonoids to inhibit or 
amplify protein functions, leading to phenotypic changes in cells and tissues 
throughout the body. As an example, flavonoids are distinguished modulators 
of mitogen-activated protein kinases (MAPKs) (7), which play a variety of 
decisive roles in the dynamic transducer system by mediating extracellular 
signals to the nucleus for transcription of adaptive and responsive genes 
(details are described in a later section). Importantly, such modulations are 
often related to the mechanisms of onset of many diseases that are considered 
to be regulated by flavonoids. In fact, quercetin (Fig.2), one of the most 
well-recognized bioactive flavonoids, has been shown to be a promising cancer 
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preventive phytochemical in many rodent experiments (8). Rutin, a quercetin 
glycoside, attenuated experimental colitis in a mouse model, possibly via the 
reduction of pro-inflammatory cytokine production (9). Furthermore,  green 
tea catechins have attracted the attention of many investigators because of their 
multiple physiological activities, including anti-obesity (10), anti-atherosclerosis 




Terpenoids are biosynthesized in all living organisms via mevalonic acid and 
methylerythritol 4-phosphate. Biosynthesis of isoprene building units 
consisting of 5 carbons (C5) is the first step in biosynthesis of terpenoids, which 
are built up through tandem connection of the C5 unit to yield mono- (C5), di- 
(C10), sesqui- (C15, di-(C20), sesta-(C25), and tri-(C30) terpenes. In addition, 
carotenoids (C40), the most well-known terpenoids, are widely used as pigments 
and food additives. Although the basic carbon skeleton is subjected to oxidation 
and hydroxylation, terpenoids are characterized as hydrophobic and lipophilic 
as compared with polyphenols. As for their physiological functions, the active 
principles in anti-inflammatory traditional medicines contain various types of 
terpenoids. As an example, the triterpenoid glycyrrhetinic acid, one of the most 
well-described phytochemicals, has been demonstrated to have marked 
anti-inflammatory activities in many experimental models (14,15). Similarly, 
both oleanolic acid (OA) and ursolic acids (UA) (Fig. 2) have exhibited 
pronounced anti-inflammatory, anti-oxidative and anti-carcinogenic activities 
(16,17). Several terpenoids are alternatively known as plant secondary 
metabolites that serve as phytoalexins. It is notable that insect-inducible 
monoterpene and sesquiterpene volatiles found in maize and rice have been 






Organosulfur phytochemicals such as isothiocyanates (ITCs) as well as those 
with the di- and tri-sulfide bonds preferentially occur in the Allium and Brassica 
genera. In those plants, ITCs are biologically dormant in the form of their 
glucosides, which are collectively termed glucosinolates. Once plants are 
invaded by insects or microorganisms, myrosinase, a hydrolytic enzyme in 
vacuoles, reacts with the glucosinolates to release bioactive ITCs, which serve as 
self-defensive compounds. Most of these phytochemicals are potent inducers of 
phase II enzymes that play pivotal roles in detoxifying procarcinogens and 
other toxins by perturbing their biological conversions into ultimate 
carcinogens (19). Sulforaphane (Fig. 2), the biochemical precursor a substance 
that is abundantly present in broccoli, has been promoted by many 
investigators for its substantial ability of inducing phase II enzymes including 
glutathione S-transferase (GST) and superoxide dismutase (SOD) (20). This 
efficacy is considered to have close associations with its potent 
anti-carcinogenesis activities in chemically and biologically induced 
carcinogenesis in several organs such as the stomach (21), colon (22), and breast 
(23). On the other hand, phytochemicals possessing di- or tri-sulfide bonds (e.g., 
diallyl trisulfide, DATS, Fig. 2) are another promising group for cancer 
prevention and therapy (24), which also have conspicuous potentials to 
contribute to cardiovascular health. In support of this notion, Yeh et al. 
demonstrated that supplementation with aged garlic extract, which is rich in 
those organosulfur compounds, was effective for lowering the plasma 
concentration of total cholesterol and LDL cholesterol in hypercholesterolemic 
men as compared with subjects who consumed a placebo (25).  
Signal transduction pathways 
General overview  
Extracellular signals are transmitted into cell via complex and well-concerted 
mechanisms. Figure 3 presents a brief general scheme showing how ligand 
stimulation produces bioactive proteins in multiple stages. Ligand binding to its 
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receptor induces functional activation of receptor-associated adaptors proteins, 
thereby transmitting signals to numerous downstream molecules, many of 
which are protein kinases. Mitogen-activated protein kinases (MAPKs), all of 
which are activated by phosphorylation, are central players that connect 
extracellular signals to transactivation of target genes (as described below in 
detail). They basically function downstream of both MAPK kinases (MAPKKs) 
and MAPK kinases (MAPKKKs). Concurrently, MAPK activation is tightly 
modulated by MAPK phosphatases (MKPs) (26), the major determinants of 
which MAPK pathways become dominant. The selectively activated MAPKs, 
together with other downstream proteins, then induce transactivation of the 
target genes, which is dependent on  transcription factors and their 
co-activators such as p300 (27). Many pro-inflammatory and oncogenic proteins 
are regulated by several distinct stages including post-transcription, translation, 
and post-translation, each of which is triggered at different time points through 
distinct mechanisms. A large portion of the mRNAs, which have an AU-rich 
element (ARE) in their 3’-untranslated regions (UTRs), is regulated by 
post-transcriptional mechanism (28). Also, translation of some cell 
cycle-regulating and tumor invasive proteins is promoted by mTOR-dependent 
pathways (29). Post-translation is the most rapid mechanism capable of 
producing bioactive proteins by one or a few proteolyses of their precursors, 
which are biologically dormant. This mechanism is well known to function with 
pro-inflammatory cytokines such as tumor necrosis factor (TNF)- and 




Anti-oxidation can be defined as a fundamental self-defense mechanism that is 
ubiquitously distributed among organisms. ROS play numerous physiological 
and pathological roles by oxidizing macro- and micro-components at the 
molecules, cellular, and tissue levels. It is evident that naturally occurring 
polyphenols and carotenoids have chemical potentials to remove harmful ROS. 
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Importantly, those functions may also have certain connections with their health 
promotion and disease preventive effects (31-34). The anti-oxidative activities of 
polyphenols are logically attributable to their catechol structures (termed ‘ortho 
diphenols’, Fig. 4A). This functional moiety has a chemical characteristic to 
scavenge ROS through formation of an o-quinone counterpart (Fig. 4B). In 
addition, polyphenols with a pyrogallol moiety, which consists of 3 consecutive 
phenolic hydroxyl groups in a single benzene ring (Fig.4A), are antioxidants 
superior to the catechol types. In contrast, monophenolic compounds, which 
essentially cannot be converted into an o-quinone, are far less effective ROS 
scavengers. Nonetheless, certain phytochemicals including those lacking 
phenolic groups possess anti-oxidative capacity by up-regulating the induction 
of anti-oxidant enzymes (20).  
The Keap1/Nrf2 system adaptively functions to protect cells from 
oxidative and electrophilic damages (35). In a normal state, the transcription 
factor Nrf2 is continuously ubiquitinated by the Cul3–Keap1 ubiquitin E3 ligase 
complex and thereby rapidly subjected to degradation in proteasomes (Fig. 5). 
Electrophilic chemicals and oxidative stresses oxidize the reactive cysteine 
residues of Keap1 in both direct and indirect manners (35). This critical step 
stabilizes Nrf2, thereby inducing robust expression of a battery of 
cytoprotective genes, including anti-oxidative genes (glutathione: GSH 
regeneration, NADPH synthesis, ROS scavenging and quenching), xenobiotic 
metabolizing genes (L-γ-glutamyl-L-cysteinyl-glycine: GSH S-transferase (GST), 
glucuronidase, sulfatase), and protein quality controlling genes (molecular 
chaperones, ubiquitin/proteasome systems) (35). Prior to translocation of Nrf2 
into the nucleus, its transcription activity is modulated by several protein 
kinases, which are simultaneously activated by stimuli. Feng et al. disclosed that 
activation of Akt and extracellular signal-regulated kinase (ERK)1/2 is required 
for OA-induced activation of Nrf2 followed by up-regulation of heme 
oxygenase (HO)-1 expression in primary rat vascular smooth muscle cells (36). 
Sauchinone, an antioxidant lignan, protects hepatocytes from acetaminophen 
toxicity via Nrf2 activation, which is dependent on protein kinase (PKC)δ, 
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leading to suppression of glycogen synthase kinase-3 (GSK)3β phosphorylation 
(37). In addition, protocatechuic acid, a simple phenolic acid as well as the main 
metabolite of anthocyanins, was found to induce antioxidant genes in J774 A.1 
macrophages in a c-Jun-N-terminal kinase (JNK)1/2-mediated and 
Nrf2-dependent manner (38). As shown in those studies, the functions of 
protein kinases responsible for Nrf2 activation are dependent on cell type- and 
types of stimulation. In addition, Nrf2 activity is critically dependent on Bach1, 
an Nrf2-repressive protein that constitutively binds to the Maf recognition 
element (39). 
 Several anti-oxidation enzymes that are Nrf2-dependent and 
–independent have been reported. For example, SODs, being ubiquitously 
expressed in cells, are Nrf2-dependent and catalyze the conversion of 
superoxide anion into molecular oxygen and hydrogen peroxide. They are 
classified into several isozymes such as cytosolic (or SOD1; Cu/Zn-SODs), 
mitochondrial (or SOD2; Mn-SOD), and extracellular SOD (or SOD3). 
Disruption of Cu/Zn-SODs may be  involved in the onset of numerous 
diseases such as familial amyotrophic lateral sclerosis (40). GSH is the most 
abundant (0.5 -10 mM in cells) and functions as an endogenous antioxidant, 
while its biosynthesis is mediated through Nrf2-dependent γ-glutamylcysteine 
synthetase (γ-GCS) as well as GSH synthetase. Likewise, selenium-coordinated 
GSH peroxidase (GPx) is also designated as an Nrf2- and GSH-dependent 
enzyme that reduces hydroperoxides and lipid peroxides into corresponding 
alcohols (41) (Fig.6). GPx consists of several subgroups, i.e., cellular GPx (cGPx 
or GPx1), gastrointestinal GPx (GIGPx or GPx2), extracellular GPx (eGPx, pGPx, 
GPx3), phospholipid hydroperoxide GPx (PHGPx or GPx4), and selenoprotein 
P (SeP or SelP). HO-1 catalyzes the oxidative degradation of heme into 
biliverdin, carbon monoxide (CO), and Fe2+ (42). Biliverdin is then converted by 
biliverdin reductase into bilirubin, which is a potent endogenous antioxidant. 
Thioredoxin (Trx) also acts as a redox sensor protein that is highly susceptible to 
oxidative stress to form intra-molecular disulfide bonds, thereby reducing 
oxidized, client proteins (43) (Fig. 6). The Trx family consists of several distinct 
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subgroups such as GSH-dependent glutaredoxins (Grx1 in cytosol and Grx2 in 
mitochondria and nucleus) and protein disulfide isomerase in the endoplasmic 
reticulum. In addition, peroxiredoxins (Prxs), which are highly expressed in 
various cellular compartments, is a peroxidase family that reduces intracellular 
peroxides with the Trx system as the electron donors (Fig. 6). There is an 
increasing body of evidence showing how oxidative stress triggers activation of 
Trx systems. In a normal state, Trx is bound to apoptosis regulating kinase 1 
(ASK1), a member of MAPKKK. Oxidation of thiol groups of Trx liberates ASK1 
to be associated with TRAF2/6, leading to enhanced phosphorylation of several 




Inflammation is a pathophysiological phenomenon that is involved in an untold 
number of acute and chronic diseases. Each human organ has the potential for 
diseases that possess an in inflammatory condition essential to the etiology. A 
considerable proportion of chronic inflammatory diseases display an overlap 
with onset and development of cancer, as seen in cases of ulcerative colitis and 
Crohn’s disease (colorectal cancer), reflux esophagitis, Barrett’s esophagus 
(esophageal carcinoma), and hepatitis (hepatocellular carcinoma) (45). 
Furthermore, inflammation has been recognized to play a pivotal role in insulin 
resistance, obesity, and diabetes (46) as well as in brain and myocardial 
infarctions that originate from vascular atherosclerosis (47). Thus, it is 
considered that regulation of inflammatory conditions provides great benefit 
for health promotion and disease prevention. In pathogenic conditions, 
inflammatory responses, which are partly described by immune cell activation, 
are sustained and exaggerated in a dysregulated manner. Also, genetic 
alterations are frequently associated with cases of chronic and pathogenic 
inflammation. For example, in an intriguing study, Kubaszek et al. reported 
discovery of a promoter polymorphism of the TNF- (G-308A) gene that 
confers increased TNF- production, even though high concentrations of 
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inflammatory cytokines are risks for type-2 diabetes (48). In addition, Hwang et 
al. showed molecular evidence indicating that polymorphisms of IL-1 
significantly affect its levels in serum (49). 
MAPK signal transduction pathways play several crucial roles in many 
aspects of immune system-mediated inflammatory responses. MAPKs, which 
belong to a large family of serine/threonine kinases, constitute major 
inflammatory signaling pathways from the cell surface to nucleus (50). There 
are 3 dominant MAPK subfamilies, ERK1/2, p38 MAPK, and JNK1/2, all of 
which compose an evolutionarily conserved family of enzymes that form a 
highly integrated network required to achieve specialized cell functions 
controlling cell differentiation, cell proliferation, and cell death, as well as 
short-term changes required for homeostasis and acute hormonal responses 
(51,52). As noted previously, the activities of these MAPKs are modulated by 
other intracellular enzymes such as MAPKKs, which add a phosphate group to 
their serine/threonine residue(s). The activities of MAPKKs, in turn, are 
controlled by MAPKKKs. To date, the enzymes that control MAPKKKs and 
their substrate specificity are incompletely understood (53). Following the 
activation of MAPKs, transcription factors present in the cytoplasm or nucleus 
are phosphorylated and activated, leading to expression of certain target genes 
for biological responses. Multiple interactions between the different MAPK 
cascades serve to integrate responses and moderate outputs. Indeed, it has been 
demonstrated that MAPKs have overlapping substrate specificities and 
phosphorylation of regulatory sites is shared among multiple protein kinases 
(51,54,55). Among the 3 major groups of MAPK signaling pathways, the ERK 
pathway is stimulated mainly by growth factors, mitogens, and tumor 
promoters (56,57), while those of p38 MAPK and JNK are activated by 
inflammatory cytokines (IL-1 and TNF-), UV light, ROS, heat and osmotic 
shock, and growth factors (56,58). Inflammatory cytokines are potent triggers of 
the MAPK pathways, which are often associated with cell growth, 
differentiation, development, and apoptosis (56,59-62). Therefore, it is 
conceivable that MAPKs and NF-B are essential elements of signaling 
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molecules that participate in inflammatory responses. 
 
Molecular targets for phytochemicals 
Polyphenols 
 
The most commonly recognized binding proteins and target molecules of 
phytochemicals are flavonoids. Hou and Kumamoto recently published a 
comprehensive and excellent review describing protein kinases as the targets of 
flavonoids (7). For the present discussion, we divided naturally occurring 




As noted above, one of the earliest reports on the specific binding protein of a 
food phytochemical was published by Tachibana and colleagues who 
uncovered a receptor for EGCg, 67LR, which was shown to have a Kd value of 
39.9 nM and mediate the EGCg-induced anti-proliferation activity in A549 
human lung cancer cells (3).Thereafter, this green tea catechin was also found to 
target 67LR for disrupting stress fibers and the contractile ring by reducing 
myosin light chain phosphorylation(63). Along a similar line, 67LR is involved 
in the EGCg-modulated cytoskeleton in association with its inhibitory activity 
toward degranulation and suppression of histamine release in KU812 human 
basophilic cells (64,65), which may account for its anti-allergy activity (66). 
Additionally, the expression of FcR1, an IgE receptor, was found to be 
down-regulated by EGCg through its interaction with 67LR (67). Interestingly, a 
eukaryotic translation initiation factor was identified with direct genetic 
screening and shown to mediate EGCg-inhibited tumor growth via 
dephosphorylation of myosin phosphatase by targeting the subunit at Thr-696 
in vitro and in vivo (68,69). Moreover, molecular mechanisms underlying the 
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anti-inflammatory activity of EGCg may partly be linked to 67LR-mediated 
down-regulation of toll-like receptor (TLR)2 (70) and TLR4 (71), suggesting 
counteractive interactions between those cell surface receptors.  
Development of new strategies for amplifying the biological functions 
of EGCg by its combination with other agents may arise from the discovery of 
67LR. For example, the combination of EGCg with all-trans retinoic acid (ATRA) 
led to a conspicuous increase in growth inhibition of B16 mouse melanoma cells 
(72). In that study, it is interesting that additive or synergistic effects by that 
combination were seen because ATRA is capable of inducing 67LR. Importantly, 
the gallate ester group in catechins may be the structural determinant of 67LR 
binding (3). Meanwhile 67LR was also shown to serve as a receptor for 
methylated derivatives of EGCg (73,74), which were found present in a unique 
tea cultivar and have potent anti-allergy activities (75-78). On the other hand, 
other binding proteins have also been identified as significant molecules that 
mediate EGCg signaling. For example, Chen et al. confirmed that EGCg is both 
a substrate and potent inhibitor of catechol-O-methyltransferase (COMT) and 
either the D- or B-ring of EGCg could induce the substrate binding pocket of 
this enzyme (79,80). Moreover, vimentin, an intermediate filament protein that 
has essential roles in cell motility and proliferation, was revealed to be a 
binding protein of EGCg (Kd = 3.3 nM) by use of a pull-down assay with 
Sepharose and proteomics (81). The same research group also reported that 
both insulin-like growth factor-I receptor (82) and Fyn kinase (83) were direct 
targets of EGCg and indispensable for its anti-cell transformation activity. 
 
Flavonols 
A common chemical characteristic of flavonols such as myricetin and quercetin 
is the presence of a hydroxyl group at the 3-position. In addition to ROS 
scavenging effects, there is ample evidence that a variety of flavonols have 
specific binding proteins, which accounts for a portion of their diverse 
biological activities. In recent years, myricetin has been shown to bind several 
protein kinases, that participate in cellular transformation and proliferation, as 
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well as inflammation. For example, Lee and colleagues provided evidence that 
myricetin (Fig. 2) is a naturally occurring inhibitor of MEK, an upstream signal 
transducer for both phorbol ester- and EGF-induced neoplastic cell 
transformation (5). Interestingly, that report showed that this flavonol inhibits 
H-Ras-induced cell transformation more potently than PD09059, a synthetic 
MEK inhibitor. Furthermore, though a number of flavonoids are bound to the 
ATP-binding domain of protein kinases, they found that the mode of MEK 
inhibition by myricetin may be dissimilar (5). Following that intriguing report, 
Jung et al. reported that myricetin suppresses UVB-induced skin cancer in mice 
probably via binding to Fyn kinase, which plays major roles in the expression of 
cyclooxygenase (COX)-2,  an inducible rate-limiting enzyme involved in 
inflammation (84). Their docking data obtained with computer simulation 
suggested that it has a high affinity to the ATP-binding site of Fyn, which is 
located between the N and C lobes of the kinase domain. Also, myricetin was 
reported to suppress UVB-induced wrinkle formation and matrix 
metalloproteinase (MMP)-9 expression by targeting Raf kinase, which has 
MEK1/2 as substrates, in an ATP-noncompetitive manner (85). In addition, 
MKK4, a protein kinase that activates JNK1/2, has been speculated to be the 
molecular target of myricetin in TNF--induced vascular endothelial growth 
factor expression in JB6 P+ mouse epidermal cells (86). Also in that report, 
myricetin was suggested to target the ATP-binding site of MKK4 based on 
computer modeling findings (86). Myricetin also binds to Akt to disrupt 
Akt-mediated activator protein-1 (AP-1) transactivation, cyclin D1 expression, 
and cell transformation, and molecular modeling results suggested that it binds 
to the ATP-binding site through hydrogen bonds (87). In another study, ex vivo 
and in vitro pull-down assays disclosed myricetin binding to JAK1, as well as 
signal transducers and activators of transcription (STAT)3 (Tyr-705 and Ser-727), 
but not to epidermal growth factor receptor (EGFR), to inhibit cell 
transformation in epidermal growth factor (EGF)-activated JB6 cells (88). 
Quercetin is one of the most frequently studied flavonoids because of 
its versatile biological, biochemical, and physiological activities including 
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anti-oxidative, anti-inflammatory, and anti-carcinogenesis effects. Like 
myricetin, quercetin was found to bind to both RAF and MEK1 in a specific 
fashion for suppressing phorbol ester-induced transformation in JB6 P+ cells (4). 
Their docking simulation data also implied that quercetin forms a hydrogen 
bond with the backbone amide group of Ser-212, which is required to stabilize 
the inactive conformation of the activation loop of MEK1. In addition, PI3K, a 
protein kinase upstream of Akt/p70S6K/ERK1/2, was shown to be a binding 
protein for quercetin to disrupt arsenite-induced COX-2 expression in rat liver 
epithelial cells (89), with similar results seen for kaempferol (Fig. 2), another 
flavonol analogous to quercetin (90). Isorhamnetin (quercetin 3'-O-methylether) 
is a naturally occurring flavonoid as well as a quercetin metabolite in biological 
systems (91-93). A recent report by Kim et al. showed that isorhamnetin directly 
binds to MEK1 in an ATP-noncompetitive manner and to phosphoinositide-3 
kinase (PI3K) in an ATP-competitive manner, leading to distinct attenuation of 




Anthocyanins are flavonoids that are notable as colorants that exhibit a reddish 
or purple color depending on pH and the presence or absence of free metal ions. 
Recently, Kang et al. reported that delphinidin (Fig. 2), a naturally occurring, 
representative anthocyanin, attenuated phorbol ester-induced neoplastic 
transformation in JB6 CI41 cells by binding to and inhibiting Raf and MEK1 
noncompetitively with ATP, leading to COX-2 down-regulation (95). This 
pigment was also found to target Fyn kinase for down-regulating 
TNF--triggered COX-2 expression in the same cell line (96). Furthermore, 
cyanidin, another major anthocyanin found in plants, suppressed UVB-induced 
COX-2 expression by targeting MKK4, MEK1, and Raf1 (97).  
 
Isoflavonoids 
Flavonoids that have a B-ring at the 3-position are categorized as isoflavonoids, 
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and are metabolized and/or decomposed in the gastrointestinal tract, especially 
by microflora (98). Equol (Fig.2), a metabolite of the soybean isoflavone 
daidzein, targets MEK1 without competing with ATP for reducing the 
ERK/p90RSK/AP-1 pathway, leading to inhibition of transformation of JB6 cells 
(99). In addition, Lee et al. found that 7,3’,4’-trihydroxyisoflavone, another 
metabolite of daidzein, inhibited EGF-induced proliferation and transformation 
of JB6 P+ cells, which may be due to its specific bindings to PI3K and 
cyclin-dependent kinase (CDK)s, leading to blockade of the Akt/GSK-3b/AP-1 
pathway (100). They also demonstrated that this daidzein metabolite 
suppressed UVB-induced skin carcinogenesis by targeting Cot and MKK4 in an 
ATP-competing manner (101). Another metabolite of daidzein, 
6,7,4’-trihydroxyisoflavone, inhibited proliferation of HCT-116 human colon 
cancer cells by targeting CDK1/2 in vitro and in vivo (102). 
 
Miscellaneous 
Resveratrol (3,5,4’-trihydroxy-trans-stilbene, Fig.2), a stilbene-type polyphenol, 
was recently demonstrated to suppress pancreatic cancer by binding LTB4 
hydrolase in cultured cells and a xenograft mouse model (103). Meanwhile, a 
pull-down assay by Kang et al. showed that caffeic acid (3,4-dihydroxycinnamic 
acid) directly inhibited Fyn kinase, and also attenuated resultant COX-2 
expression in JB6 P+ cells and mouse skin (104). Another study found that 
luteolin (3',4',5,7-tetrahydroxyflavone) inhibited PKC and Src kinase in an 
ATP-competitive manner, and also decreased UVB-induced tumor incidence, 





Both UA and OA have long been recognized to have anti-inflammatory and 
anti-cancer activities in laboratory animals. In addition, they are also effective 
for protecting against chemically induced liver injury in laboratory animals 
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(106-111). Although the mechanisms by which they suppress inflammation and 
tumor development are not clear, it has been reported that UA attenuated the 
expression of inducible nitric oxide synthase (iNOS) and COX-2 expression via 
NFB repression in lipopolysaccharide (LPS) or interferon (IFN)- activated 
mouse M (112). Furthermore, Subbaramaiah K et al. (113) demonstrated that 
treatment with UA suppressed TPA-mediated induction of COX-2 protein and 
synthesis of prostaglandin (PG)E2 in human mammary and oral epithelial cells. 
In a study of its action mechanism, UA suppressed TPA-mediated activation of 
PKC, ERK1/2, JNK1/2, and p38 MAPK, while it also blocked the binding of AP-1 
to the COX-2 promoter (113). These findings are important for understanding 
the anti-inflammatory properties of UA. In contrast, You et al. (114) reported 
that UA induced nitric oxide (NO) and TNF- production via NFB activation 
in resting RAW264.7 mouse M, implying that the effects of UA on NFB 
activities are dependent on the biological status of the target M. This 
background led us to investigate the potential proinflammatory effects of UA in 
vitro and in vivo as well as the underlying molecular mechanisms. We initially 
attempted to examine the effects of UA on production of inflammatory 
cytokines [IL-1, IL-6, TNF-, and MIF (Mmigration inhibitory factor)] in 
resting RAW264.7 mouse M(115). Interestingly, the amount of intracellular 
MIF protein decreased when the cells were stimulated with UA, which strongly 
suggests that MIF protein stored in the intracellular compartment is transported 
and released from cells upon stimulation with this triterpenoid. UA also 
induced activation of ERK1/2, but not JNK1/2 or p38 MAPK, while the 
involvement of ERK2 and to a lesser extent ERK1 following activation caused 
by the release of MIF was revealed in experiments using siRNAs. In addition, in 
another study, we found that UA markedly increased the protein production of 
IL-1, IL-6, and MIF, but not of TNF-, in pMfrom ICR mice (Fig. 7). Also, UA 
induced intracellular ROS generation with resultant activation of the ERK1/2 
and p38 MAPK, but not JNK1/2, pathways. Our data showed that scavenger 
receptor (SR) CD36 mRNA and protein were expressed in pM in constitutive 
manners, while pretreatment of cells with the anti-CD36 antibody significantly 
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suppressed IL-1 release and UA bound to CD36 on M. Furthermore, the 
amount of IL-1 released from UA-treated pM of CD36-deficient mice was 
markedly lower than from wild-type mice, suggesting that CD36 is one of the 
membrane receptors of UA, while it remains to be determined whether UA also 
binds with other SRs or proteins that are involved in IL-1 release. Together, 
these results suggest that the effects of UA in experiments with RAW264.7 cells 




In 1999, we identified zerumbone (Fig.2), an electrophilic sesquiterpene present 
in Zingiber zerumbet Smith (shampoo ginger) (Fig.8A), as a potent inhibitor of 
phorbol ester-induced EB virus activation in Raji cells (116). Thereafter, a 
number of studies, including ours, demonstrated that it has marked potential 
for regulating the pathologies of lifestyle-related diseases including cancer and 
inflammation (117). Oral administration of zerumbone markedly suppressed 
dextran sulfate sodium-induced colitis in mice (118), as well as 
azoxymethane-induced formation of aberrant crypt foci (119) and adenomas 
and adenocarcinomas (120) in rat colons. Interestingly, the anti-cell proliferating 
activity of zerumbone was found to be cancer- but not normal cell-specific, 
though the mechanism is not fully understood (121). On the other hand, 
evidence of its anti-inflammatory and xenobiotic-metabolizing activities have 
been shown to be related to the major mechanisms of action by which it 
prevents chemical carcinogenesis. For example, the above-mentioned 
chemopreventive effects accompanied reductions of PGE2 and COX-2 protein 
expressions in colonic mucosa (118,120). Using RAW264.7 M, we 
demonstrated that zerumbone attenuated COX-2 expression via a 
post-transcriptional mechanism (122). COX-2 mRNA expression is regulated by 
at least 3 distinguishable stages in a complex manner. The earliest induction 
mechanism is related to the finding that COX-2 mRNA contains an ARE in its 
UTR, which has critical roles for the mRNA stability (123). Several reports of 
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different cell types have shown that activation of p38 MAPK leads to 
stabilization of COX-2 mRNA. Also, a substrate for p38 MAPK, i.e., 
MAPK-activated protein kinase 2, phosphorylates certain candidate proteins 
such as HSP27 (124), heterogeneous nuclear ribonucleoprotein A0(125), and Hu 
antigen R (HuR) (126), which bind to AREs, thereby contributing to rapid 
synthesis of COX-2 protein. As noted above, phase II enzymes play central roles 
in anti-oxidation and detoxification of undesired, harmful chemicals through 
conjugation reactions. This mechanism participates in anti-carcinogenesis by 
preventing ultimate carcinogens from their interactions with DNA.  
It is important to note that large numbers of such xenobiotic chemicals 
are subjected to the detoxification system for modulating the expressions of 
phase I, II, or both types of enzymes in biological systems. We previously 
reported that zerumbone induced phase II drug-metabolizing enzymes in rat 
hepatocytes (127). This property was confirmed by following in vivo 
experiments, in which zerumbone was topically applied to mouse skin to 
increase the mRNA expression levels of phase II enzymes such as SOD and GPx, 
whereas those of CYP1A1 and 1B1 were not significantly changed. Meanwhile, 
we recently generated zerumbone-bound Sepharose gels to explore its binding 
proteins in vitro (128) (Fig.8B). Incubation of cell lysate from RAW264.7 M with 
this chemical probe resulted in the identification of HuR and Keap1 as in vitro 
binding protein of this compound (128). In addition, competitive experiments in 
that study with zerumbone showed that those bindings are specific, because 
-humulene, a biologically inactive analogous compound did not show any 




Organosulfur phytochemicals activate the Keap1/Nrf2 system to provide the 
host with an amplified self-defense capacity. Sulforaphane (Fig.2), a 
characteristic constituent of broccoli, prevented chemical carcinogenesis in 
rodents, and induced phase II enzymes in cell cultures and animal studies (129). 
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Hu et al. published a very interesting observation that sulforaphane reacts with 
at least 4 cysteine residues of Keap1 including C-151 based on mass 
spectrometry analysis (130). On the other hand, Heiss et al. showed that 
sulforaphane either reacts with NFB by binding to essential cysteine residues 
of p65, or interacts with GSH or other redox regulators like Trx and Ref-1, 
which are relevant for NFB function in M for exhibiting anti-inflammatory 
activity (131). In addition, mutation of critical cysteines in the DNA-binding 
domain of the AP-1 component (Cys-154 in c-Fos and Cys-272 in c-Jun) lead to 
loss of sensitivity to sulforaphane to inhibit UVB-induced transactivation of 
AP-1 in HaCaT human keratinocyte (132). It is also worth pointing out that 
activation of Kea1/Nrf2 is related to its anti-inflammatory activity through 
repression of the p38 MAPK-dependent pathway (133,134).  
Microarray analysis performed by Hu et al. using Nrf2 knockout mice 
(-/-) identified Nrf2-dependent, sulforaphane-inducible genes (135). In addition 
to anti-oxidative and detoxifying enzymes, the identified genes included HSP 
and ubiquitin/26S proteasome subunits, raising the possibility that this 
phytochemical affects the protein maintenance control system by up-regulating 
molecular chaperones and degrading disused proteins. Consistent with this 
observation, a recent study by Gan et al. showed that sulforaphane treatment 
remarkably induces HSP27, leading to enhancement of proteasome activity 
(136). The authors speculated that thiol groups in heat shock factor 1, a key 
transcription factor for a set of HSPs, might be modified by sulforaphane for its 
transactivation. Jordit et al. revealed that allyl ITC, the major pungent in 
mustard oil, mediates its excitatory effects by activating transient receptor 
potential A1 (TRPA1), a member of the ion channel family, suggesting a cellular 
and molecular target for the pungent action of mustard oils, and supports the 
notion of a fundamental role for TRP channels as ionotropic cannabinoid 
receptors (137). Thereafter, various compounds with an ITC moiety were shown 
to activate TRPA1 in a manner that relies on covalent modification of cysteine 
residues within the cytoplasmic N terminus of the channel (138). Other studies 
have reported 1’-acetoxychavicol acetate (ACA), a phenyl propanoid in Alpinia 
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galanga (great galangal), as a promising cancer preventive agent (139,140), while 
a more recent report by Narukawa et al. revealed that ACA is a more potent 
TRPV1 agonist than ally ITC (141). Importantly, one of its chemical 
characteristics, i.e., electrophilicity due to the exo-methylene group (142), is 
similar to that of ITC and zerumbone. 
Some food stuffs from the Allium genera, which exhibit a particularly 
pungent aroma, are recognized to contain sulfur-containing compounds such as 
ITCs and diallyl disulfide (DADS). Bautista et al. found that DATS (Fig.2) 
directly activates the Ca2+ excitatory ion channel TRPA1 (143). It is tempting to 
speculate that different plant genera, i.e., Allium and Brassica, have developed 
evolutionary convergent strategies to target TRPA1 channels on sensory nerve 
endings to achieve chemical deterrence. On the other hand, treatment with 
DATS, but not diallyl monosulfide and DADS, led to tubulin polymerization 
disruption (144). This phenomenon may be mediated by specific oxidative 
modification of Cys-12 and Cys-354 to form S-allylmercaptocysteine as 
suggested by peptide mass mapping with liquid chromatography-tandem mass 
spectrometry analysis (144). It is also important to note that TRPA1 is targeted 
by a series of -unsaturated aldehydes (145-148), such as cinnamaldehyde 
and 4-hydroxy-2-nonenal (HNE). Thus it might be possible that bioactive 
phytochemicals with similar chemical properties (149), including zerumbone, 
partially exert their physiological activities through this receptor. Capsaicin, the 
pungent constituent of chili peppers, binds to and activates transient receptor 
potential vanilloid 1 (TRPV1) for transducing signals related to pain. 
Importantly, TRPV1 is not only a prime target for the pharmacological control 
of pain but also a useful target for drug development to treat various disorders 
including cardiovascular and gastrointestinal diseases (150). This receptor is a 
nonselective cation channel with significant permeability to calcium, protons, 
and large polyvalent cations. TRPV1 is the most polymodal TRP channel, and is 
activated by numerous stimuli, including heat, voltage, vanilloids, lipids, and 
protons/cations (151). This receptor also acts as a molecular integrator of 
physical and chemical stimuli in peripheral nociceptor terminals and plays a 
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critical role in thermal inflammatory hyperalgesia (151). TRPV1 binding by 
capsaicin has drawn the attentions of numerous investigators, because it 
stimulates lipid catabolism by targeting adipogenesis (152), which is likely 
associated with the anti-obesity effects of capsaicin. Meanwhile, α-lipoic acid 
(LA), (Fig.2) is a thiol antioxidant distributed in many vegetables, including 
broccoli and spinach (153). There are multiple lines of in vitro and in vivo 
evidence that LA is a promising phytochemical for delaying or preventing 
lifestyle-related diseases such as neurodegenerative disease (154,155), 
hypertension and nephrotoxicity(156), and type 2 diabetes (157). Also, 
accumulating evidence has revealed that LA is a striking inducer of the 
Keap1/Nrf2 system for exhibiting anti-oxidant activity as seen in several cell 
lines (158-160). In addition, Suh et al. presented impressive findings that, while 
the functional capability of the Keap1/Nrf2 system declines with aging in rats, 
i.p. administration with LA considerably attenuated that decay (161).  
 
Do synthetic drugs target only one or multiple biomolecules? 
In contrast to extremely specific bioprobes, such as specific antibodies and 
oligonucleotides, small molecules have a limited specificity to bind 
biomolecules. Nonetheless, it is important to note that synthetic drugs exhibit 
reasonably high binding affinities toward target proteins as compared with 
natural compounds. This perception is readily justified, because those drugs are 
designed to optimally fit targets on the basis of data from X-ray analysis of 
crystallized target proteins and computer docking simulations. It is tempting to 
speculate that there are significant opportunities for these drugs to have 
associations with biomolecules other than their intended targets. Celecoxib, a 
synthetic COX-2 inhibitor, is a representative drug for support of this 
hypothesis. This agent has been shown to have a conspicuous ability to prevent 
chemical carcinogenesis in the colons of rodents (162) and a high-risk 
population (163) by targeting COX-2. On the other hand, using COX-2 deficient 
mice Pang et al. documented unexpected findings that celecoxib induced 
apoptosis in gastric cancer cells through a COX-2-unrelated Akt/GSK3/NAG-1 
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pathway, raising the possibility that it targets functional protein(s) other than 
COX-2 (164). In parallel, celecoxib reduced the proliferation of COX-2 deficient 
HCT-15 colon cancer xenografts in nude mice (165). Using a celecoxib analog, 
Kelp et al. presented findings showing that the 3-phosphoinositide-dependent 
protein kinase-1(PDK1)/Akt signaling pathway is responsible for the 
anti-proliferative effects of this agent in prostate cancer cells (166). Moreover, 
Lev-Ari et al. concluded that the physiological concentration range (5-10 M) of 
celecoxib is too low to inhibit cancer cell proliferation, and speculated that other 
target molecule(s) and mechanisms may play a role (167). These unexpected 
actions of celecoxib may be related to its harmful effect(s). In accordance with 
this speculation, the potential risk of cardiovascular dysfunctions with celecoxib 
revealed in clinical studies, may be attributable to its binding to carbonic 
anhydrase (168). Likewise, nonsteroidal anti-inflammatory drugs (NSAIDs) 
have been reported to occasionally show their pharmacological activities 
through COX-independent mechanisms. Kashfi and Rigas found that NSAIDs 
have multiple targets that include phosphodiesterases, PDK1, peroxisome 
proliferator-activated receptors, and carbonic anhydrases (169). Along a similar 
line, the pyridinyl imidazole p38 MAPK inhibitors (SB 203580 and SB 202190) 
are potent casein kinase 1 inhibitors that block stress-induced CREB 
phosphorylation at Ser-111, which was importantly found to be p38 
MAPK-independent (170). Recently, Xie et al. developed a novel computational 
strategy to identify protein-ligand binding profiles on a genome wide scale for 
elucidating the molecular mechanisms associated with the adverse drug effects 
of cholesteryl ester transfer protein inhibitors, which will help to transform the 
conventional drug discovery process (single-target/single-drug) to a new 
paradigm (multi-target/multi-molecule) (171). Overall, researchers should keep 
in mind that chemical compounds, even highly-selective drugs, have a 
probability to bind biomolecules in unexpected manners, which may be 
relevant to their side-effects and/or other concealed physiological activities.  
Phytochemicals are believed to have more opportunities for  
interactions with biological proteins as compared with drugs, based on the fact 
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that they are structurally simple. A recent evaluation by Chavez et al. may 
support this notion, as HNE, a small molecule with an -unsaturated 
carbonyl group, was found to covalently bind to multiple house-keeping 
proteins, including Cys-295 of the tubulin R-1B chain, Cys-351 and Cys-499 in 
R-actinin-4, Cys-328 of vimentin, Cys-369 of D-3-phosphoglycerate 
dehydrogenase, and His-246 in aldolase A in THP-1 human monocytes (172). It 
should be emphasized that there are a number of phytochemicals, including 
zerumbone and sulforaphane, that have chemical characteristics similar to HNE 
and their binding manners is presumably non-specific like HNE, rather than 
specific. Interestingly, the food colorant erythrosine B perturbed multiple 
interactions between tumor necrosis factor superfamily members and their 
corresponding receptors (TNF-R-TNFα, CD40-CD154, BAFF-R-BAFF, 
RANK-RANKL, OX40-OX40L, 4-1BB-4-1BBL, EGF-R-EGF) (173), which shows 
the possibility that multiple interactions of natural products can be positively 
evaluated. Also, the major tissue component extracellular matrix, was modified 
by small-molecules via multiple bindings, which may be associated with cell 
cycle regulation (174) (81,144).  
It has been shown that phytochemicals bind to specific receptors and 
proteins for exhibiting biological and physiological activities. On the other hand, 
few studies have investigated their non-specific bindings, which might be 
related to potential side-effects, have some beneficial effects, or had no effects. 
To date, no method is available to quantify the non-specific interactions 
between ligands and biomolecules. However, McLure et al. investigated the 
non-specific bindings of synthetic drugs by incubating human liver microsomes 
with  1-anilinonaphthalene-8-sulfonate (175), a fluorescence agent. This 
experimental method may be advantageous for safety assessment and 
prediction of unwanted side-effects.  
 
Phytochemicals are not originally produced for human use 
Most, if not all, of plant secondary metabolites are biosynthesized for the 
purpose of self-defense and adaptation to environmental stresses. For example, 
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polyphenols are produced for protection against sunlight-induced oxidative 
damages, while bactericidal and insecticidal phytochemicals serve as ‘chemical 
weapons’ that combat invading organisms (Fig. 9). Indeed, it is reasonable to 
speculate that antioxidants play beneficial roles in both plants and humans by 
scavenging harmful ROS. On the other hand, it is logically puzzling that the 
defensive chemicals produced in plants also exhibit health promotion and 
disease preventive effects in experimental animals and humans. One clue is 
related to the fact that phytochemicals essentially function as non-nutrients and 
xenobiotics in humans, which is supported by the findings showed that the 
bioavailability of polyphenols, for example, is very poor and they are 
immediately subjected to biological conjugation systems for rapid excretion. 
Moreover, it is very important to note that most of those metabolic conversions 
dramatically reduce their biological activities (176-178). In addition, the 
exclusion mechanisms of phytochemicals have partial associations with those of 
hazardous toxins (179,180), while they are in contrast to those of nutrients 
(181,182), vitamins (183,184) and minerals (185,186), most of which are actively 
incorporated via specific receptors and transporters. Interestingly, Son et al. 
presented the idea that phytochemicals exert hormetic effects on animals (187). 
‘Hormesis’ is a physiological mechanism by which sub-toxic doses of 
physical, chemical, or biological stressors trigger the adaptive mechanism to 
protect from subsequent more severe stresses, though an overdose results in 
catastrophe, as shown by U-shaped dose responses (187). Thus, mild stress 
from exposure to xenobiotics generates positive effects for health promotion 
and disease prevention by adaptive up-regulation of self-defense systems. 
Alcohol consumption is a practical example to describe hormesis since low and 
medium levels of intake, in general, actually promote health (188). Although the 
mechanism is not fully understood, alcohol consumption-induced elevation of 
alcohol and aldehyde dehydrogenases (189) may be protective against 
environmental aldehyde toxins. It is of magnitude importance to indicate that 
hormesis by chemical exposure has some convergence with that by dietary 
energy restriction (190) and exercise (191), both of which definitively contribute 
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to longevity and health promotion. 
 
Conclusion 
Both endogenous and exogenous electrophiles in subtoxic doses elevate 
detoxifying activity via the Keap1/Nrf2 system, which promotes their excretion 
by glutathionylation. Exposure of skin to moderate UVB light also activates this 
protective system, leading to mitigation of oxidative skin damage (192). 
Together, a wide variety of environmental stressors stimulates human 
self-defensive systems for adaptation. When the stress burden is beyond 
capacity, severe damage and toxicity become dominant, and occasionally lethal 
(Fig. 10). Recent reports of the side-effects of supplements especially at high 
doses (193-195) may reflect an imbalance between chemical stress and capacity. 
Identification of the target molecules of phytochemicals currently occupies a 
significant portion of research in the field of food functional science. Such a 
direction is challenging, though it will lead to not only a better understanding 
of the mechanisms of action but also to more precise assessment of side-effects 
and potential toxicity.  
Molecular-targeted food functional science investigations may generate 
powerful strategies with combinations of phytochemicals and/or synthetic 
drugs for synergistic efficacy. Noticeable differences between phytochemicals 
and drugs can be seen in their target specificity. The broad range of target 
binding properties of the former may be associated with their ‘mild’ 
bioactivities as compared to rationally designed drugs, while their non-specific 
or ‘dirty’ bindings have no significant involvement with the mechanisms of 
potential toxicity. Alternatively, their broad range of bindings to biological 
proteins might lead to some hormetic effects, thus potentiating the capability of 
self-defense systems. Therefore, the putative non-target effects of 
phytochemicals, which are largely absent in drugs, may exhibit significant 
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AP-1 activator protein-1 
ARE AU-rich element 
ASK1 apoptosis regulating kinase 1 
ATRA all-trans retinoic acid 
AUF-1 AU-rich element/poly(U)-binding/degradation factor-1 
CDK cyclin-dependent kinase 
CO carbon monoxide 
COMT catechol-O-methyltransferase  
DADS diallyl disulfide  
DATS diallyl trisulfide 
EGCg (-)-epigallocatechin-3-gallate 
EGF epidermal growth factor  
EGFR epidermal growth factor receptor 
ERK extracellular signal-regulated kinase 
iNOS inducible nitric oxide synthase 
JNK c-Jun-N-terminal kinase 
GCS glutamylcysteine synthetase 
GPx GSH peroxidase 




GST glutathione S-transferase 
HNE 4-hydroxy-2-nonenal 
HSP heat shock proteins 
HO heme oxygenase  
HuR Hu antigen R 
IL interleukin 
ITC isothiocyanate 
LA α-lipoic acid 
LPS lipopolysaccharide 
MAPK mitogen-activated protein kinase  
MAPKK/MEK/MKK MAPK kinase 
MAPKKK MAPK kinase kinase 
M macrophages  
MIF M migration inhibitory factor 
MKP MAPK phosphatases 
MMP matrix metalloproteinase 
NF nuclear factor 
NO nitric oxide 
NSAIDs anti-inflammatory drugs 
OA oleanolic acid 
PDK-1 3-phosphoinositide-dependent protein kinase-1 
PG prostaglandin 
PI3K phosphoinositide-3 kinase 
pM peritoneal M
PKC protein kinase  
Prx peroxiredoxin 
ROS reactive oxygen species 
SeP selenoprotein P 
SOD superoxide dismutase 
STAT signal transducers and activators of transcription 
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TLR toll-like receptor 
TNF tumor necrosis factor 
TRPA1 transient receptor potential A1 
Trx thioredoxin 
UA ursolic acid 
UB ultraviolet 
UTR untranslated region 
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Chemical structures of phytochemicals referred to in this manuscript. EGCg, 
(-)-epigallocatechin-3-gallate; UA, ursolic acid; OA, oleanolic acid; DATS, diallyl 
trisulfide; LA, α-lipoic acid. 
 
Figure 3 
Brief scheme of generalized signal transduction pathways. 
 
Figure 4 
A. Chemical structures of phenol, catechol, and pyrogallol. B. Superoxide anion 
generation from catechol. 
 
Figure 5 
Action mechanism underlying Nrf2 activation following oxidative and 
electrophilic stresses. In a normal state, the transcription factor Nrf2 is 
continuously ubiquitinated by the Cul3–Keap1 ubiquitin E3 ligase complex and 
thereby rapidly subjected to degradation in proteasomes. Electrophilic 
chemicals and oxidative stresses oxidize the reactive cysteine residues of Keap1 
for reducing the E3 ligase activity. This critical step stabilizes Nrf2 and thereby 
induces robust expression of a battery of cytoprotective genes. Prior to 
translocation of Nrf2 into the nucleus, its transcription activity is modulated by 
several protein kinases, which are simultaneously activated by stimuli. 
 
Figure 6 
Antioxidant system based on glutathione (GSH), thioredoxin (Trx), and  
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peroxiredoxins (Prx). Trx acts as a redox sensor protein that is highly 
susceptible to oxidative stress to form intra-molecular disulfide bonds, thereby 
reducing oxidized, client proteins. Peroxiredoxins (Prxs), which are highly 
expressed in various cellular compartments, comprise a peroxidase family that 
reduces intracellular peroxides with the Trx system as the electron donor. 
 
Figure 7 
Proposed molecular mechanisms by which UA induces pro-inflammatory 
cytokines in murine M. Aggregated UA is recognized by CD36 and then ROS 
are intracellularly generated, presumably by NOX. This process triggers the 
activation of MAPK pathways and NFB for promoting transcription of 
pro-inflammatory mediator (such as iNOS, TNF-, and IL-1) genes, leading to 
the expression of pro-inflammatory mediators for intracellular protein 




A. Protein cysteine thiol has potential to make an adduct with zerumbone via 
nucleophilic addition. B. Preparation method of Sepharose zerumbone. ECH 




Plants are exposed to severe environmental stresses that induce them to 
biosynthesize secondary metabolites such as antioxidants, antifeedants, 




General scheme of stress adaptation. Environmental stress has a potential to 
strength the adaptation system, allowing the host to acquire stronger resistance 
 43 
 
to harsher stresses. However, when the stress exceeds the defense capacity, it 
becomes toxic and occasionally lethal. 










